Bridgeside Telehealth Review

What Bridgeside Telehealth charges

• BPC-157: $300/mo — "$99 Consultation | $300 for Peptides if prescribed" — a one-off medication charge, not a monthly rate, with the $99 visit billed separately and waived when therapy is not clinically appropriate
• CJC-1295: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" that applies to every peptide here, with a separate $99 consultation; sold as a CJC-1295 with ipamorelin protocol
• Ipamorelin: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" that applies to every peptide here, with a separate $99 consultation; sold as a CJC-1295 with ipamorelin protocol
• Semax: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" with a separate $99 consultation; the page groups it as "Selank / Semax" and states no strength or format
• Epitalon: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" with a separate $99 consultation; the page states no strength, format or supply length
• GHK-Cu: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" that applies to every peptide here, with a separate $99 consultation; GHK-Cu is named outright on the recovery page and no strength, format or supply length is stated
• Sermorelin: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" that applies to every peptide here, with a separate $99 consultation; the growth-hormone page states no strength, format or supply length
• Tesamorelin: $300/mo — the same flat "Peptide medication: $300 (if prescribed)" that applies to every peptide here, with a separate $99 consultation; the growth-hormone page states no strength, format or supply length

Bridgeside Telehealth also sells 1 compound this site boards without publishing a price for it: NAD+.

One price, whichever peptide it turns out to be

The medication charge does not move with the compound. Whether the outcome of the consultation is a recovery peptide, a growth-hormone-axis peptide or a neuro peptide, the published figure is the same one.

That is unusual and it is genuinely useful to a shopper who does not yet know what they will be prescribed. It removes the incentive to steer a consultation toward a more expensive product, because there is not one.

The site also says there is no charge for the visit at all if peptide therapy is not clinically appropriate, and that additional peptides are only considered after the first month rather than sold as a stack up front. Both are restraints a seller does not have to publish.

The operating entity is named in the Terms of Use as Bridgeside Telehealth LLC, with those Terms governed by Texas law, so the company behind the brand is established by a document rather than inferred.

Two price structures, both live

The home page says the total cost is the medication figure, consultation included. Every peptide page says the consultation is charged on its own and the medication figure sits on top of it.

Those cannot both be true, and the difference between them is the whole consultation fee. This site records the product-page structure because that is where the peptide prices are published, and it records the contradiction rather than picking a winner quietly.

The FAQ makes it worse rather than better. It asks whether the medication charge is a subscription, and the answer field still reads Tab Item Content — the theme's placeholder text, left in place on the question a shopper most needs answered.

A placeholder in an FAQ is a small thing that says something larger about how closely the pricing pages are maintained. It is also the only published answer to whether the charge recurs.

A name inside a disclaimer is not an offer

The FDA boilerplate on this site lists a string of compounded peptides including TB-500 and MOTS-c. No page offers either one as a therapy.

This site does not record them as sold. A regulatory disclaimer naming a category of substance is not a catalog, and counting a name inside one as an offer would put a seller on two boards it never advertised on.

What the category pages do name outright is narrow. GHK-Cu and NAD+ are named directly, sermorelin and tesamorelin appear on the growth-hormone page, and the rest of the menu reads as categories rather than as products with strengths.

NAD+ is recorded as sold here with no price attached. The flat structure applies to it like everything else, but the page it is named on was not captured in the pass behind this row, and this site does not attach a figure to a source it has not recorded.

Forty-four states, none of them named

The site states that it is licensed in forty-four states and enumerates none of them. A count tells a shopper the odds, not the answer, and this site does not reconstruct a list from a number.

Ten of the twenty-three sellers compared here publish a state list. This is one of the thirteen that do not.

No compounding pharmacy is named either, only a licensed U.S. compounding pharmacy. Six of the twenty-three sellers here name the facility that fills an order.

None of these peptides is an FDA-approved finished drug. The site's own disclaimer says as much about the category, which is the part of that boilerplate worth reading.

How we verified this

• Read each peptide category page and recorded the consultation and medication figures exactly as published, together on the same line.
• Compared the home page's total-cost sentence against the product pages' two-line structure and recorded both rather than reconciling them.
• Read the FAQ and recorded the unfilled placeholder answer to the subscription question verbatim.
• Read the FDA boilerplate and confirmed that TB-500 and MOTS-c appear only there, then left both undeclared on this row.
• Recorded the forty-four-state claim as published and confirmed no enumeration appears anywhere on the site.
• Confirmed the operating entity and governing law from the seller's own Terms of Use.